Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, Aledex, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Post by skyhi0on Aug 11, 2006 1:01pm
102 Views
Post# 11214306

The following....

The following....is a snipit from the MARCH 22 NEWS RELEASE. since then we have seen a publication of previously known advances in this science. EXACTLY WHAT DID .....LEADERSHIP, VISION, AGGRESSIVE GROWTH & DEVELOPEMENT STRATEGY mean in that release. This one is dying on the vine !!! Kane Biotech Inc (C-KNE) - News Release Kane Biotech names Froehlich as president 2006-03-22 09:50 ET - News Release Shares issued 14,623,156 KNE Close 2006-03-21 C$ 0.60 Mr. Marcus Enns reports Kane Biotech Inc. has appointed Gord Froehlich as president. Mr. Froehlich, a 30-year veteran of managing and commercializing biotechnology ventures, brings leadership and vision as Kane Biotech charts an aggressive growth and development strategy. Prior to his appointment, Mr. Froehlich was Kane's vice-president, business development. He has also held senior leadership positions in the biotechnology industry as vice-president of Monsanto Canada
Bullboard Posts